Table 2.
Response data
| Patient No. | Cycles | Bone marrow CLL cells (%) | Marker LN (cm) | Spleen size (cm) | Responsee | ||||
|---|---|---|---|---|---|---|---|---|---|
| C1D1 | C3D21 | EOT | C1D1 | EOT | C1D1 | EOT | |||
| Group 1 | |||||||||
| JAK2001 | 7 | 40 | 25 | 18 | 1.5 | 0.7 | NA | NA | PR |
| JAK2002 | 7 | 6 | 25 | 46 | 2.2 | 2.7 | 11.7 | 11.1 | PD |
| JAK2003 | 5a | 4 | 9 | NA | 3.6 | 9.7 | 12.5 | 13.3 | PD |
| Group 2 | |||||||||
| JAK2005 | 7 | 58 | 68 | 54 | 0.8 | 0.7 | 12.2 | 11.9 | SD |
| JAK2007 | 7 | 9 | 8 | 1 | 2.8 | 2.3 | 14.8 | 12.6 | PR |
| JAK2008 | 7 | 15 | 13 | 23 | 1.8 | 1.6 | 11.5 | 11.6 | SD |
| Group 3 | |||||||||
| JAK2009 | 7 | 0 | 0 | 0 | 0.9 | 0.8 | 13.1 | 12.4 | SD |
| JAK2010 | 7 | 4 | 2 | 3 | 0.9 | 0.9 | NA | NA | SD |
| JAK2011 | 5b | 7 | 24 | NA | 1.5 | 0.7 | 10.6 | 10.6 | SD |
| Group 4 | |||||||||
| JAK2012 | 3c | 2 | 4 | NA | 0.8 | 0.8 | 9.4 | 9.4 | SD |
| JAK2014 | 7 | 5 | 7 | 2.9 | 0.9 | 0.9 | 13.3 | 12.7 | SD |
| JAK2015 | 6d | 0 | 0 | NA | 1.8 | 1.8 | 12.9 | 12.3 | SD |
NA, not available.
a
Discontinued due to disease progression.
b
Stopped 1 week into cycle 5 due to skin cancer and radiation therapy.
c
Stopped after three cycles at patient's request.
d
Cycle 7 not given at discretion of patient and investigator.
e
PR = partial response, PD = progressive disease, SD = stable disease.